Ratings & reviews
Helps students see their full potential.
Brings enthusiasm and expertise to class.
Encourages students to ask questions.
Inspires a love for learning in everyone.
Inspires curiosity and a thirst for knowledge.
Taught by or worked with Yazi?
Add your rating. It takes about 30 seconds.
About Yazi
Professor Yazi Ke is the Deputy Director (Research and Operations) of the Dementia Research Centre and a Professor in the Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University. She leads a research group focused on RNA regulation in neurodegeneration. After obtaining her PhD in Neuroscience, Ke established herself as a leading expert in pathomechanisms of frontotemporal dementia (FTD) and motor neuron disease (MND). Her career includes postdoctoral research at the Neuroscience Laboratory, Prince of Wales Medical Research Institute, before joining Macquarie University. Ke's research has elucidated critical roles of TDP-43 proteinopathy in FTD and amyotrophic lateral sclerosis (ALS), developing innovative gene therapy approaches, including cell-targeted and immune-resistant vectors for single-dose treatments. These advancements have led to multiple patents, such as 'Treatment of dementia' and 'Treatment of excitotoxicity-related conditions' co-invented with Lars Ittner in 2022.
Ke has secured major funding, including the NHMRC Career Development Fellowship in 2016 for investigating novel pathomechanisms and therapeutic targets in neurodegenerative diseases, the Betty and John Laidlaw MND Research Prize in 2020 for novel therapeutic strategies targeting TDP-43 in MND, an NHMRC Ideas Grant of approximately $687,000 in 2023 for advancing gene therapy in FTD and MND, and a $550,000 MRFF grant in 2024 to test new MND drugs. Her key publications encompass 'Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal lobar degeneration' (Neuron, 2024), 'TDP-43 pathology and functional deficits in wild-type and humanized mice' (2023), 'Efficient Gene Expression in Human Stem Cell Derived-Cortical Organoids' (2022), and earlier influential works like 'Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia' (2008). With over 5,800 citations and an established biotechnology company, Celosia Therapeutics, where she serves as Chief Operating Officer, Ke's contributions significantly influence therapeutic development for neurodegenerative disorders.
Trending Research & Publication News
SPARC Cost of Knowledge Study: 95% Public Investment in Articles
Photo by Precondo CA on Unsplash
AI Research Scooping: OpenAI & Anthropic Priority Disputes
Photo by Brecht Corbeel on Unsplash
Informa Taylor & Francis Split & Clarion Deal | AcademicJobs
Photo by Anne Nygård on Unsplash
arXiv Two-Submission Monthly Cap Explained | AcademicJobs
Photo by Kelly Sikkema on Unsplash
Cell Press Bribery Investigation: Cancer Cell Editor Accused
Photo by Markus Winkler on Unsplash
Society Journal Sales & Nonprofit Consolidations | AcademicJobs
Photo by Philip Strong on Unsplash